On October 14, 2026, the FDA announced the Rare Disease Framework Initiative to develop a fit-for-purpose framework for rare disease drug development, led by its...
A study led by Rare Diseases International finds rare disease patients in Colombia wait an average of 25 months for a diagnosis, and up to...
The FDA on October 14 expanded Anktiva (nogapendekin alfa inbakicept-pmln) to adults with BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer, as ImmunityBio works through a March...
Mexico’s pharmaceutical and medical-device industry chamber, Canifarma, says 650–700 medicine listings have been removed from Mercado Libre under a June 2026 brand-protection agreement, and warns...
Brazil’s federal health ministry began dispensing nine new cancer drugs through the public Sistema Único de Saúde (SUS) network this week, for more than 116,000...
Explore More Topics:
LATEST
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.